The first-generation BTK inhibitor, ibrutinib, is an orally administered medication approved in Japan for the treatment of both CLL and WM; however, it may be associated with treatment resistance and an increased frequency of cardiovascular adverse events (AEs), including atrial fibrillation and hypertension [7]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.